Developer docs
API playgroundTry for free, no card

Search company profiles

SiteOne Therapeutics

Full company profile

uuid0000d4z

Namestring
SiteOne Therapeutics
Legal namestring
SiteOne Therapeutics Inc.
Company typeenum
Private
Founded yearint
2010
Descriptiontext

SiteOne Therapeutics was a privately-held clinical-stage biotechnology company founded in 2010 and headquartered in South San Francisco, California. The company focused exclusively on developing non-opioid therapeutics for acute, neuropathic, visceral, and musculoskeletal pain through selective inhibition of the NaV1.8 sodium ion channel, a validated target in pain signal transmission. Its lead investigational candidate, STC-004, is a small molecule designed to interrupt pain signaling without engaging opioid receptors, offering a non-addictive alternative to conventional opioid analgesics in a market context shaped by roughly 80,000 US opioid overdose deaths annually and 51.6 million US adults living with chronic pain.

As a pre-commercial entity, SiteOne generated no product revenue. Its operating model relied on equity financings from biotech-focused investors — including Amgen, Mission BioCapital, Novo Holdings, OrbiMed, and Wellington Management — supplemented by up to $15 million in non-dilutive grant funding from the National Institute on Drug Abuse through the NIH HEAL Initiative in May 2023. The company operated with 11-50 employees and advanced STC-004 through clinical development without an independent commercial infrastructure. In May 2025, Eli Lilly and Company acquired SiteOne Therapeutics for up to $1 billion to expand its pain management portfolio beyond its core cardiometabolic franchise, integrating the NaV1.8 program alongside its broader non-opioid pain strategy that was catalyzed by Vertex's FDA approval of Journavx.

Short descriptiontext

SiteOne Therapeutics was a clinical-stage biotech developing non-opioid pain therapeutics via selective NaV1.8 ion channel inhibition, with lead candidate STC-004 targeting acute and chronic pain, acquired by Eli Lilly in May 2025 for up to $1 billion.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
non-opioid pain therapeutics, NaV1.8 ion channel inhibitors, clinical-stage biotechnology, pain management therapeutics, selective sodium channel modulators
Industry1 code
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
Product category
Non-opioid Pain Therapeutics
No data
Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

SiteOne Therapeutics develops investigational non-opioid pain therapeutics using selective NaV1.8 ion channel inhibition. The company's lead candidate, STC-004, is being advanced as a non-addictive alternative to opioids for the treatment of acute, neuropathic, visceral, and musculoskeletal pain. The platform is built around peripherally restricted NaV1.8 inhibition to deliver pain relief while avoiding central nervous system side effects and opioid-associated addiction and abuse liabilities.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • First novel non-opioid pain drug approved in decades (Vertex's Journavx) validates the non-opioid pain market opportunity
Product overview1 text field

SiteOne Therapeutics is a biotechnology company developing non-opioid pain therapeutics. The company's primary product candidates include STC-004 and the NaV1.8 inhibitor, both targeting pain through selective NaV1.8 ion channel inhibition. These investigational treatments aim to provide non-addictive alternatives to opioids for pain management. The company was acquired by Eli Lilly in May 2025 for up to $1 billion.

Product and service1 record
1STC-004
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-05-01
Description

Eli Lilly acquired SiteOne Therapeutics in May 2025 for up to $1 billion to expand its pain management portfolio with non-addictive chronic pain therapies. The acquisition is part of Lilly's broader strategy to build its non-opioid pain pipeline beyond its core cardiometabolic business, leveraging the commercial success of GLP-1 franchise products.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Cara Therapeutics is a clinical-stage biotech developing difelikefalin, a peripheral KOR agonist approved for chronic kidney disease-associated pruritus and explored in pain indications. Cara is a direct peer as a focused pain and pruritus therapeutic developer, addressing similar unmet needs in non-opioid alternatives.

TypeEmerging player
Description

Centrexion is a clinical-stage biotech focused on developing non-opioid therapeutics for chronic pain conditions, including CNTX-4971 (capsaicin-based injection) for knee osteoarthritis pain. Centrexion is an emerging player addressing the same non-opioid pain thesis as SiteOne through a distinct delivery mechanism.

TypeBroad incumbent
Description

Amgen led SiteOne's $15 million Series 2 financing in 2017, signaling strategic interest in SiteOne's NaV1.8 program. As a major biotech with broad inflammation and pain franchises, Amgen is a relevant incumbent peer in non-opioid pain therapeutics development.

TypeDirect peer
Description

Trevena developed OLINVYK (oliceridine), an FDA-approved opioid for moderate-to-severe acute pain in hospital settings, focused on providing differentiated pain management. Trevena is a direct peer as a pain-focused biopharmaceutical company developing novel pain therapeutics.

TypeBroad incumbent
Description

Pfizer has pursued non-opioid pain therapeutics, including the NGF inhibitor tanezumab (co-developed with Eli Lilly) for chronic pain conditions. Pfizer competes in the same non-opioid pain strategic category as SiteOne, although through a different mechanism of action (NGF inhibition versus NaV1.8 inhibition).

TypeDirect peer
Description

Collegium Pharmaceutical is a specialty pharmaceutical company focused on responsible pain management, with a portfolio including abuse-deterrent opioids (Xtampza) and non-opioid pain therapies. Collegium is a direct peer as a commercial-stage pain management specialist addressing both opioid and non-opioid pain markets.

TypeBroad incumbent
Description

Eli Lilly acquired SiteOne in May 2025 for up to $1 billion to expand its non-opioid pain portfolio. As a global top-tier pharmaceutical developer with established commercial infrastructure, Lilly is both the acquirer/parent and a broader incumbent developing pain therapeutics alongside its cardiometabolic franchise.

TypeDirect peer
Description

Vertex developed and gained FDA approval for Journavx (suzetrigine), the first-in-class selective NaV1.8 inhibitor for moderate-to-severe acute pain. It is the most directly comparable peer to SiteOne, pursuing the identical mechanism of action in pain and establishing the regulatory and commercial benchmark for NaV1.8 selective inhibition.

TypeBroad incumbent
Description

Regeneron has been a major developer of NGF inhibitor pain therapies, including fasinumab for chronic pain conditions (osteoarthritis and chronic low back pain). Regeneron competes in the non-opioid pain category through a distinct mechanism (NGF) but addresses the same patient population and prescriber base as SiteOne.

TypeEmerging player
Description

Tonix Pharmaceuticals is a clinical-stage company developing CNS-focused therapeutics including TNX-102 SL for chronic pain conditions such as fibromyalgia. Tonix is an emerging player in the non-opioid pain space, addressing overlapping chronic pain indications with SiteOne's programs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SiteOne Therapeutics

Non-opioid Pain Therapeuticssiteonetherapeutics.com

SiteOne Therapeutics was a clinical-stage biotech developing non-opioid pain therapeutics via selective NaV1.8 ion channel inhibition, with lead candidate STC-004 targeting acute and chronic pain, acquired by Eli Lilly in May 2025 for up to $1 billion.

What SiteOne Therapeutics does

SiteOne Therapeutics was a privately-held clinical-stage biotechnology company founded in 2010 and headquartered in South San Francisco, California. The company focused exclusively on developing non-opioid therapeutics for acute, neuropathic, visceral, and musculoskeletal pain through selective inhibition of the NaV1.8 sodium ion channel, a validated target in pain signal transmission. Its lead investigational candidate, STC-004, is a small molecule designed to interrupt pain signaling without engaging opioid receptors, offering a non-addictive alternative to conventional opioid analgesics in a market context shaped by roughly 80,000 US opioid overdose deaths annually and 51.6 million US adults living with chronic pain.

As a pre-commercial entity, SiteOne generated no product revenue. Its operating model relied on equity financings from biotech-focused investors — including Amgen, Mission BioCapital, Novo Holdings, OrbiMed, and Wellington Management — supplemented by up to $15 million in non-dilutive grant funding from the National Institute on Drug Abuse through the NIH HEAL Initiative in May 2023. The company operated with 11-50 employees and advanced STC-004 through clinical development without an independent commercial infrastructure. In May 2025, Eli Lilly and Company acquired SiteOne Therapeutics for up to $1 billion to expand its pain management portfolio beyond its core cardiometabolic franchise, integrating the NaV1.8 program alongside its broader non-opioid pain strategy that was catalyzed by Vertex's FDA approval of Journavx.

SiteOne Therapeutics firmographics

Firmographics
Name
SiteOne Therapeutics
Legal name
SiteOne Therapeutics Inc.
Website
https://siteonetherapeutics.com
Company type
Private
Founded year
2010
Operating status
Acquired
Headcount range
1–10 employees
Short description
SiteOne Therapeutics was a clinical-stage biotech developing non-opioid pain therapeutics via selective NaV1.8 ion channel inhibition, with lead candidate STC-004 targeting acute and chronic pain, acquired by Eli Lilly in May 2025 for up to $1 billion.
Ownership category
akta.pro rank

SiteOne Therapeutics industry classification

Industry
Product category
Non-opioid Pain Therapeutics
akta.pro industry
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Non-opioid pain therapeutics
  • NaV1.8 ion channel inhibitors
  • Clinical-stage biotechnology
  • Pain management therapeutics
  • Selective sodium channel modulators

Where SiteOne Therapeutics is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Markets served

SiteOne Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

SiteOne Therapeutics product offering

Product offering

Core offering

SiteOne Therapeutics develops investigational non-opioid pain therapeutics using selective NaV1.8 ion channel inhibition. The company's lead candidate, STC-004, is being advanced as a non-addictive alternative to opioids for the treatment of acute, neuropathic, visceral, and musculoskeletal pain. The platform is built around peripherally restricted NaV1.8 inhibition to deliver pain relief while avoiding central nervous system side effects and opioid-associated addiction and abuse liabilities.

Product overview

SiteOne Therapeutics is a biotechnology company developing non-opioid pain therapeutics. The company's primary product candidates include STC-004 and the NaV1.8 inhibitor, both targeting pain through selective NaV1.8 ion channel inhibition. These investigational treatments aim to provide non-addictive alternatives to opioids for pain management. The company was acquired by Eli Lilly in May 2025 for up to $1 billion.

Differentiator

Problem solved

Functional benefit

Products and services

  • STC-004

Quantifiable outcome

  • First novel non-opioid pain drug approved in decades (Vertex's Journavx) validates the non-opioid pain market opportunity

Companies that use SiteOne Therapeutics

Customer profile

Segments1 record

Ideal customer profiles2 records

SiteOne Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

SiteOne Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Eli Lilly and CompanyflagshipStrategic or Co-development Partner · 1 May 2025Eli Lilly acquired SiteOne Therapeutics in May 2025 for up to $1 billion to expand its pain management portfolio with non-addictive chronic pain therapies. The acquisition is part of Lilly's broader strategy to build its non-opioid pain pipeline beyond its core cardiometabolic business, leveraging the commercial success of GLP-1 franchise products.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

SiteOne Therapeutics competitors and assessment

Company assessment

Direct peers

  • Cara Therapeutics: Cara Therapeutics is a clinical-stage biotech developing difelikefalin, a peripheral KOR agonist approved for chronic kidney disease-associated pruritus and explored in pain indications. Cara is a direct peer as a focused pain and pruritus therapeutic developer, addressing similar unmet needs in non-opioid alternatives.
  • Trevena Inc. Trevena developed OLINVYK (oliceridine), an FDA-approved opioid for moderate-to-severe acute pain in hospital settings, focused on providing differentiated pain management. Trevena is a direct peer as a pain-focused biopharmaceutical company developing novel pain therapeutics.
  • Collegium Pharmaceutical: Collegium Pharmaceutical is a specialty pharmaceutical company focused on responsible pain management, with a portfolio including abuse-deterrent opioids (Xtampza) and non-opioid pain therapies. Collegium is a direct peer as a commercial-stage pain management specialist addressing both opioid and non-opioid pain markets.
  • Vertex Pharmaceuticals: Vertex developed and gained FDA approval for Journavx (suzetrigine), the first-in-class selective NaV1.8 inhibitor for moderate-to-severe acute pain. It is the most directly comparable peer to SiteOne, pursuing the identical mechanism of action in pain and establishing the regulatory and commercial benchmark for NaV1.8 selective inhibition.

Emerging players

  • Centrexion Therapeutics: Centrexion is a clinical-stage biotech focused on developing non-opioid therapeutics for chronic pain conditions, including CNTX-4971 (capsaicin-based injection) for knee osteoarthritis pain. Centrexion is an emerging player addressing the same non-opioid pain thesis as SiteOne through a distinct delivery mechanism.
  • Tonix Pharmaceuticals: Tonix Pharmaceuticals is a clinical-stage company developing CNS-focused therapeutics including TNX-102 SL for chronic pain conditions such as fibromyalgia. Tonix is an emerging player in the non-opioid pain space, addressing overlapping chronic pain indications with SiteOne's programs.

Broad incumbents

  • Amgen: Amgen led SiteOne's $15 million Series 2 financing in 2017, signaling strategic interest in SiteOne's NaV1.8 program. As a major biotech with broad inflammation and pain franchises, Amgen is a relevant incumbent peer in non-opioid pain therapeutics development.
  • Pfizer: Pfizer has pursued non-opioid pain therapeutics, including the NGF inhibitor tanezumab (co-developed with Eli Lilly) for chronic pain conditions. Pfizer competes in the same non-opioid pain strategic category as SiteOne, although through a different mechanism of action (NGF inhibition versus NaV1.8 inhibition).
  • Eli Lilly and Company: Eli Lilly acquired SiteOne in May 2025 for up to $1 billion to expand its non-opioid pain portfolio. As a global top-tier pharmaceutical developer with established commercial infrastructure, Lilly is both the acquirer/parent and a broader incumbent developing pain therapeutics alongside its cardiometabolic franchise.
  • Regeneron Pharmaceuticals: Regeneron has been a major developer of NGF inhibitor pain therapies, including fasinumab for chronic pain conditions (osteoarthritis and chronic low back pain). Regeneron competes in the non-opioid pain category through a distinct mechanism (NGF) but addresses the same patient population and prescriber base as SiteOne.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

SiteOne Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SiteOne Therapeutics leadership team

Management profile

Number of profiles

Profiles6 records

SiteOne Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SiteOne Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SiteOne Therapeutics

What does SiteOne Therapeutics do?

SiteOne Therapeutics develops investigational non-opioid pain therapeutics using selective NaV1.8 ion channel inhibition. The company's lead candidate, STC-004, is being advanced as a non-addictive alternative to opioids for the treatment of acute, neuropathic, visceral, and musculoskeletal pain. The platform is built around peripherally restricted NaV1.8 inhibition to deliver pain relief while avoiding central nervous system side effects and opioid-associated addiction and abuse liabilities.

Is SiteOne Therapeutics a public or private company?

SiteOne Therapeutics is a private company. It is classified as corporate owned and is currently acquired.

When was SiteOne Therapeutics founded?

SiteOne Therapeutics was founded in 2010. It employs 1 to 10 people.

Where is SiteOne Therapeutics based?

SiteOne Therapeutics is headquartered in South San Francisco, United States, in the North America region.

Who are SiteOne Therapeutics's main competitors?

Direct peers on record are Cara Therapeutics, Trevena Inc., Collegium Pharmaceutical and Vertex Pharmaceuticals. Emerging players are Centrexion Therapeutics and Tonix Pharmaceuticals. Broad incumbents are Amgen, Pfizer, Eli Lilly and Company and Regeneron Pharmaceuticals.

Does SiteOne Therapeutics have an API?

No public API is recorded for SiteOne Therapeutics.

What industry is SiteOne Therapeutics in?

SiteOne Therapeutics's product category is Non-opioid Pain Therapeutics. Its primary akta.pro industry code is HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceLilly is pharma’s top dog, placing first in innovation and invention: IDEAEli Lilly has become the first pharmaceutical company to rank first in both innovation and invention categories in IDEA Pharma's eight-year history, supported by a 45% year-on-year surge in annual earnings to $65.2 billion in 2025, driven primarily by its incretin franchise including Mounjaro ($23B, up 99% YoY) and Zepbound ($13.5B, up 175% YoY). The company reinvested its financial gains into its development pipeline, securing key approvals including weight-loss pill Foundayo, Omvoh's Crohn's disease expansion, and Inluriyo for breast cancer, while also acquiring Verve Therapeutics and SiteOne Therapeutics to boost its invention rating. Merck retained its second-place innovation ranking, while Sanofi made the most dramatic move, jumping 19 spots to third place.openPR.comOverview of Segmentation, Market Dynamics, and Competitive Landscape in the Small Molecule Targeted Therapy MarketThe small molecule targeted therapy market is projected to reach $120.64 billion by 2030, growing at a 9.3% compound annual growth rate, driven by rising demand for personalized medicine, genomics integration in drug discovery, and increased focus on improved safety profiles. Eli Lilly and Company acquired SiteOne Therapeutics Inc. in May 2025 to expand its pain management portfolio with non-addictive chronic pain therapies. In June 2025, Kura Oncology Inc. secured FDA approval for ziftomenib, an oral targeted therapy for adults with relapsed or refractory acute myeloid leukemia harboring NPM1 mutations.BioSpaceOpinion: New Painkillers Critical To Fight Opioid Epidemic, Broader Pain CrisisIn an opinion piece, Tris Pharma executives argue that the pain management field is dangerously stagnant, with opioids—first used millennia ago—still dominating treatment for moderate to severe pain despite causing 80,000 overdose deaths in the U.S. in 2023 and leaving 51.6 million adults suffering from chronic pain, a burden costing over $600 billion annually. Recent breakthroughs offer hope: Vertex Pharmaceuticals received FDA approval in January 2025 for Journavx (suzetrigine), the first novel non-opioid pain drug in decades, while Eli Lilly acquired SiteOne Therapeutics in May 2025 for up to $1 billion, and Latigo Biotherapeutics raised $135 million in 2024, signaling renewed pharmaceutical industry investment. The authors call for sustained research funding, regulatory incentives, and provider adoption to transform pain management and address both the opioid epidemic and the parallel crisis of undertreated pain.PR NewswireLilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidanceEli Lilly and Company reported Q3 2025 revenue of $17.60 billion, a 54% increase year-over-year driven by volume growth from Mounjaro and Zepbound, with reported EPS of $6.21 and non-GAAP EPS of $7.02. The company raised its 2025 full-year revenue guidance to $63.0-$63.5 billion and reported acquired in-process research and development charges of $655.7 million primarily related to the acquisition of SiteOne Therapeutics. Pipeline momentum included positive Phase 3 results for orforglipron across diabetes and obesity with planned global regulatory submissions by year-end, plus FDA approval of Inluriyo for certain advanced breast cancer patients.ModernhealthcareHealthcare M&A Mid-Year InsightThe first half of 2025 revealed mixed healthcare M&A activity, with life sciences and pharmaceuticals dominating deal volume at over 250 transactions, driven by innovation in cell and gene therapies, oncology, and rare disease treatments. Notable acquisitions included Eli Lilly's purchase of SiteOne Therapeutics, Madison Dearborn Partners' acquisition of NextGen Healthcare, and Northwell Health's acquisition of Nuvance Health, reflecting ongoing consolidation across hospital systems and physician practices. The sector faces headwinds from policy changes under the One Big Beautiful Bill Act, which may drive further consolidation as health systems adapt to Medicaid eligibility restrictions and potential end of ACA premium tax credits.PR NewswireLilly reports second-quarter 2025 financial results and raises guidanceEli Lilly and Company reported Q2 2025 revenue of $15.56 billion, a 38% increase year-over-year driven by strong volume growth from Zepbound and Mounjaro, with reported EPS increasing 92% to $6.29. The company raised its 2025 full-year revenue guidance by $1.5 billion to a range of $60 billion to $62 billion and completed acquisitions of SiteOne Therapeutics and Verve Therapeutics during the quarter. Pipeline advancements included positive Phase 3 results for orforglipron in obesity, Mounjaro's cardiovascular protection data, and Jaypirca's head-to-head win versus Imbruvica in CLL/SLL.Business & FinancialPostoperative Pain Pipeline 2025: FDA Updates, Therapy Innovations, And Clinical Trial Landscape Analysis By Delveinsight Allay Therapeutics, Siteone Therapeutics, Lipocure, Flexion TherapeuticsDelveInsight's 2025 report on the postoperative pain pipeline covers 40+ companies developing 50+ therapies, including INSB-200, BB-106, and HSK21542. HSK21542, a kappa opioid agonist, was studied in two Phase 3 trials in China for abdominal surgery pain. The report also assesses route of administration, molecule type, and market drivers and barriers.The Globe and Mail1 Underrated Reason to Buy This Market-Beating StockEli Lilly announced a $1 billion cash acquisition of SiteOne Therapeutics, targeting non-opioid oral pain medicine. The company's revenue outside diabetes and obesity products accounted for nearly 28% of its top line, with Verzenio and Taltz generating significant sales. Eli Lilly's GLP-1 drugs continue to drive growth, but its diversified portfolio offers additional investment appeal.citybizLilly To Acquire SiteOne TherapeuticsEli Lilly agreed to acquire SiteOne Therapeutics, a biotech developing Nav1.8 inhibitors for pain. The deal includes STC-004, a Phase 2 ready Nav1.8 inhibitor, with SiteOne shareholders potentially receiving up to $1.0 billion in cash. The transaction is subject to customary closing conditions.BioSpaceLilly to expand its pain pipeline with acquisition of SiteOne TherapeuticsEli Lilly and Company announced its acquisition of SiteOne Therapeutics, a biotechnology firm developing pain treatment drugs, with a deal potentially valued at up to $1 billion. The transaction aims to advance Lilly's non-opioid pain management portfolio, focusing on the drug candidate STC-004.